- Home
- PAYS vs DAWN Comparison
PAYS vs DAWN Comparison
Compare PAYS & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYS | DAWN |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.4M | 624.8M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PAYS | DAWN |
|---|---|---|
| Price | $5.45 | $8.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $8.06 | ★ $26.56 |
| AVG Volume (30 Days) | 372.6K | ★ 2.6M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | $74,879,428.00 | ★ $133,672,000.00 |
| Revenue This Year | $41.20 | $15.51 |
| Revenue Next Year | $20.62 | $49.99 |
| P/E Ratio | $42.18 | ★ N/A |
| Revenue Growth | ★ 32.61 | 31.11 |
| 52 Week Low | $1.80 | $5.64 |
| 52 Week High | $8.88 | $13.53 |
Technical Indicators
Market Signals| Indicator | PAYS | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 48.36 |
| Support Level | $5.11 | $8.13 |
| Resistance Level | $5.60 | $8.67 |
| Average True Range (ATR) | 0.20 | 0.48 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 74.98 | 25.82 |
Price Performance
Historical ComparisonAbout PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.